About MD Tirzepatide — An Independent Clinical Literature Digest

About this site

MD Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'MD' in our name is editorial framing — a position we occupy relative to the clinical literature. We read the trial protocols, summarise the findings, and cite our sources. We are a reading room for the SURPASS, SURMOUNT, SYNERGY-NASH, SURMOUNT-OSA, and SUMMIT trial programmes — not a healthcare practice.

Tirzepatide is an FDA-approved prescription medicine. The decision to use it is a clinical decision that belongs to a licensed prescriber and an individual patient. This site does not participate in that decision.

Every page on this site carries numbered citations. Every quantitative claim maps to a peer-reviewed study or an authoritative regulatory source. When the evidence base has gaps or limitations, we say so. When a finding is preclinical only, we say so. When a safety signal is theoretical rather than confirmed in humans, we say so.

We do not use brand names for tirzepatide in our editorial content. We use only the international nonproprietary name, as recommended in the academic literature.

This site has no affiliation with the manufacturer of tirzepatide or with any pharmaceutical company.